Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Naofumi Takamatsu
Preclinical Evaluation of Biomarkers Associated With Antitumor Activity of MELK Inhibitor
Oncotarget
Oncology
Related publications
Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
Preclinical Antitumor Activity of SST0116CL1: A Novel Heat Shock Protein 90 Inhibitor
International Journal of Oncology
Cancer Research
Oncology
Preclinical Evaluation of M30 and M65 ELISAs as Biomarkers of Drug Induced Tumor Cell Death and Antitumor Activity
Molecular Cancer Therapeutics
Cancer Research
Oncology
Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models
International Journal of Cancer
Cancer Research
Oncology
Preclinical Evaluation of the Antitumor Activity of Bortezomib in Combination With Vitamin C or With Epigallocatechin Gallate, a Component of Green Tea
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Characterization of a Novel PERK Kinase Inhibitor With Antitumor and Antiangiogenic Activity
Cancer Research
Cancer Research
Oncology
Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma
Oncotarget
Oncology
